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Effectiveness of psychological treatments for
depression and alcohol use disorder delivered by
community-based counsellors: two pragmatic
randomised controlled trials within primary
healthcare in Nepal
Mark J. D. Jordans, Nagendra P. Luitel, Emily Garman, Brandon A. Kohrt, Sujit D. Rathod, Pragya Shrestha,
Ivan H. Komproe, Crick Lund and Vikram Patel
Background
Evidence shows benefits of psychological treatments in low-
resource countries, yet few government health systems include
psychological services.
Aim
Evaluating the clinical value of adding psychological treatments,
delivered by community-based counsellors, to primary care-
based mental health services for depression and alcohol use
disorder (AUD), as recommended by the Mental Health Gap
Action Programme (mhGAP).
Method
Two randomised controlled trials, separately for depression and
AUD, were carried out. Participants were randomly allocated
(1:1) to mental healthcare delivered by mhGAP-trained primary
care workers (psychoeducation and psychotropic medicines
when indicated), or the same services plus individual psycho-
logical treatments (Healthy Activity Program for depression and
Counselling for Alcohol Problems). Primary outcomes were
symptom severity, measured using the Patient Health
Questionnaire – 9 item (PHQ-9) for depression and the Alcohol
Use Disorder Identification Test for AUD, and functional impair-
ment, measured using the World Health Organization Disability
Assessment Schedule (WHODAS), at 12 months post-enrolment.
Results
Participants with depression in the intervention arm (n = 60) had
greater reduction in PHQ-9 and WHODAS scores compared with
participants in the control (n = 60) (PHQ-9: M = −5.90, 95% CI
−7.55 to −4.25, β = −3.68, 95% CI −5.68 to −1.67, P < 0.001,
Cohen’s d = 0.66; WHODAS: M = −12.21, 95% CI −19.58 to −4.84,
β = −10.74, 95% CI −19.96 to −1.53, P= 0.022, Cohen’s d = 0.42).
For the AUD trial, no significant effect was found when com-
paring control (n = 80) and intervention participants (n = 82).
Conclusion
Adding a psychological treatment delivered by community-
based counsellors increases treatment effects for depression
compared with only mhGAP-based services by primary health
workers 12 months post-treatment.
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The global burden associated with mental disorders is high, espe-
cially for depression and alcohol use disorder (AUD).1 The vast
majority of people with mental illness who live in low- and
middle-income countries (LMICs) do not have access to adequate
care,2 where only 1 person in every 27 with depression receives
effective care.3 There is increasing evidence for the effectiveness of
psychological treatments implemented by non-specialists in LMIC
settings.4 Recent reviews demonstrate an effect size of 0.46 for
depression outcomes in psychological treatments delivered by
non-specialists in LMICs5 and promising outcomes for depression
and AUD treatments by non-specialists health workers in primary
and community healthcare in LMICs.6 Recent publications empha-
sise the need for research that assesses the efficacy of brief and flex-
ible interventions that can be adapted to meet the needs of
individuals across cultural contexts and employed to increase
access to services.6,7 Specific psychological treatments – including
motivational interviewing for AUD and behaviour activation tech-
niques for depression – are recommended as first-line care by the
World Health Organization (WHO) Mental Health Gap Action
Programme (mhGAP) Intervention Guide, a set of evidence-based
clinical guidelines for non-specialist health workers and service pro-
viders to detect and treat mental illness.8 However, most mhGAP
implementation in the government health systems of LMICs does
not include these recommended specific psychological treatments
because of a lack of time for primary healthcare workers to
provide such care, the need for greater intensity training and super-
vision than standard 1–2 week mhGAP trainings and lack of
patients’ time for repeated weekly visits to primary care centres to
receive the services.9 Therefore, alternative sustainable approaches
for delivery of psychological treatments are needed. One proposed
model to surmount this barrier is through the use of psychological
service providers, for example counsellors, who can be deployed to
deliver these psychological interventions in community settings as a
complement to the diagnostic and medication management services
provided through mhGAP-trained health workers in primary care
facilities. Given the scarcity of resources in LMICs, we are interested
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in evaluating the feasibility of the same non-specialist service pro-
vider delivering psychological interventions in primary health and
community settings for multiple disorders.
This study aimed to evaluate the effectiveness of adding
community-based, counsellor-delivered psychological interventions
for adults who initiated mhGAP-based primary care services for
depression and AUD in Nepal.
Method
Context: Programme for Improving Mental
Health Care
The Programme for Improving Mental Health Care (PRIME) aims
to evaluate the feasibility, acceptability and outcomes of a multi-
faceted district level mental healthcare plan (MHCP) that targets
the health facility, community and health system in five LMICs:
Ethiopia, India, Nepal, South Africa and Uganda.10 The MHCP in
Nepal has been described in detail previously.11 The programme
was implemented in Chitwan, a predominantly rural district in
southern Nepal. The total population of Chitwan was 579 984 at
the time of the study. The literacy rate of Chitwan district is
78.9%, which is higher than the national average of 67%.12 In the
district of Nepal in which this trial took place, a representative com-
munity survey found that 11.2% of adults screened positive for
depression and 5% screened positive for AUD.13 Among this
group, treatment from primary care facilities was sought by 1.8%
of those that screened positive for depression and 1.3% of those
for AUD.12
The MHCP comprised interventions at the community, health
facility and health service organisation levels.11 The community
level included community sensitisation, proactive case detection14,15
and adherence support through home-based care. The facility-level
packages included training and supervision for health workers
to detect, diagnose and initiate treatment (i.e. emotional support,
psychoeducation and psychotropic medication) for individuals
with a diagnosis of a priority disorder, as well as referrals to specia-
lised care following the mhGAP Intervention Guide.8 Finally, the
health service organisation level included ensuring reliable supply
of psychotropic medication, mechanisms for monitoring, capacity
building and resource mobilisation. This package was available to
all respondents enrolled in the study. The interventions delivered
by primary care health workers are based on mhGAP guidelines
and include assessment, psychoeducation, pharmacological treat-
ments and initiating referral.
Study design
The two randomised controlled trials (RCTs) analysed here were
nested in two treatment cohort studies, which have been described
elsewhere in detail.16 Briefly, the primary objectives of the cohort
studies were to evaluate the clinical-, social- and disability-related
effects of treatment for depression or AUD. These treatments
were initiated and delivered by health workers who were based in
ten primary healthcare facilities in Chitwan, a district in southern
Nepal. Adults (age≥ 16 years) with depression (n = 120) or with
AUD (n = 162) were recruited upon diagnosis and followed up 3
and 12 months later. We included individuals that were recruited
for the PRIME cohort studies of depression and AUD. Inclusion
for the cohort study was determined by health worker diagnosis
using the mhGAP guidelines for assessment and clinical decision
making. Exclusion criteria for the depression and AUD cohorts
were as follows: pregnancy, needing urgent medical treatment, diag-
nosis with psychosis or epilepsy (these patients were recruited for
two different cohort studies) and being unable to communicate
clearly. For the cohort studies, decision rules were established for
the allocation to cohorts in case of comorbidity: psychosis or epi-
lepsy took precedence over AUD, and AUD over depression. This
meant that some of the AUD participants had also been diagnosed
with depression as a secondary diagnosis (n = 3, which is too small a
subgroup to test for potential moderator effects). No changes to
methods were made after commencement of the trials.
Randomisation
Among the participants who were already recruited into cohort
studies evaluating mhGAP-based standards of care for depression
or AUD, we individually randomised half to receive a psychological
treatment (Healthy Activity Program [HAP]17 for depression and
Counselling for Alcohol Problems [CAP]18 for AUD). After each
participant completed their baseline assessments for the cohort
study (without imposing a randomisation constraint), randomisa-
tion was done by the research coordinator in Kathmandu (N.P.L.)
by using computer-generated random numbers (in SPSS Version
22 for Windows). A list of numbers (1–400) was randomised so
that each number corresponded to either the treatment or control
group. The ID code of each new eligible participant was sent to
the research coordinator, who then matched it to the next
number on the list. For those allocated to the treatment condition,
the ID code was send to the study field coordinator and clinical
supervisor so that they could connect these respondents to research
assistant and community counsellors, respectively.
Intervention service providers
For the treatment arms of the trials, psychological treatments deliv-
ered by six community-based counsellors (four female, two male)
were added. These counsellors were members of the local commu-
nity who had completed at least a high-school education. The coun-
sellors received a base training which included 400 h of classroom
learning, 150 h of clinical supervision, 350 h of practice and 10 h
of personal therapy spread out over 6 months.19 The community-
based counsellor training program has been used widely in the
humanitarian non-governmental sector in Nepal for the past 15
years, and an estimated 400 community counsellors have been
trained throughout the country during that time. In addition, for
this study, the counsellors followed a 10 day combined training
for HAP17 (for depression) and CAP18 (for AUD).
Study interventions
Participants in both study arms received the services that were part
of the newly developed MHCP (standard of care), as described
above. The control group participants therefore received mhGAP-
based interventions (psychoeducation and pharmacological treat-
ment when indicated) delivered by primary health workers. The
participants in the treatment arm received additionally either
HAP (for depression) or CAP (for AUD).
HAP is a manualised intervention that is delivered individually
over 6–8 weekly sessions and consists of behavioural activation as
the core therapeutic framework, which includes psychoeducation,
behavioural assessment, activity monitoring, activity structuring,
problem solving and activation of social networks. CAP is a manua-
lised motivational activation intervention of four sessions delivered
weekly, also delivered individually. It consists of detailed personal
assessment, developing cognitive and behavioural skills (i.e. drink
refusal skills, handling peer pressure, problem solving skills and
handling difficult emotions) and managing potential relapses.
These interventions have been developed through a systematic
process of merging global evidence and contextually appropriate
practices for treatment of depression and AUD. Recent trials in
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India have demonstrated the effectiveness and cost-effectiveness of
HAP20,21 and CAP22,23 to reduce severity of symptoms and to
increase remission. Both manuals were translated from the original
language into Nepali by a bilingual Nepali psychologist, who had
also received a training of trainers from the original developers.
Bi-weekly supervision by the same trainer was delivered for the
counsellors during the trials. The same service providers delivered
both interventions within a routine primary healthcare setting.
Outcome measures
The primary outcomes were symptom severity and disability at 12
months follow-up. For the depression trial, symptom severity was
assessed by the Patient Health Questionnaire – 9 item (PHQ-9), a
self-reported screening tool designed for use in various medical set-
tings. The PHQ-9 has been widely used and validated in primary
care, medical out-patients and specialist medical services.24 The
respondents are asked to score nine common symptoms of depres-
sion in the past 2 weeks. It has a 4-point rating scale from 0 ‘not at
all’ to 3 ‘always’. The PHQ-9 has been translated and validated in a
primary care population in Chitwan, Nepal; with an area under the
curve of 0.94 (95% CI 0.87–0.99), sensitivity of 1.00 and specificity
of 0.40 for a cut-off score of≥5 and a Cronbach’s alpha of 0.84 in the
validation sample.25
For the AUD trial, symptom severity was assessing by the
Alcohol Use Disorder Identification Test (AUDIT), developed by
WHO as a screening tool for AUD in primary healthcare.26 The
AUDIT has been validated in Nepal and a cut-off score of ≥9 has
been recommended as the threshold to identify probable alcohol
dependence or alcohol misuse for both males (sensitivity 96.7,
specificity 91.7) and females (sensitivity 94.3, specificity 91.4), and
has a Cronbach’s alpha of 0.82.27
In both depression andAUD samples, disability was assessed using
the 12-itemWHODisability Assessment Schedule (WHODAS 2.0),
measuring functional impairment over the previous 30 days. The
instrument has been validated in a range of settings and cultures28
and has been previously used in Nepal.29,30 Cronbach’s alpha for
the WHODAS is 0.82 (depression trial participants) and 0.86
(AUD trial participants).
The secondary outcomes were response rates for depression,
defined as at least 50% reduction in PHQ-9 score compared with
baseline, and reduction to low-risk drinking levels rates for AUD,
defined as subthreshold AUDIT score (below nine).20,22 All instru-
ments were administered as part of the parent cohort study,
therefore no additional measures were included for the trials.
In addition, we have included demographic measures (gender,
age, marital status, religion, caste, education level and employment).
We also collected process indicators (number of HAP and CAP
sessions). No changes to outcomes were made after the start of
the trials.
Procedures
Data collection was conducted by 12 research assistants who had
completed at least an undergraduate degree. The research assistants
received a 1 month training covering the topics of interviewing
skills, rapport building, informed consent, ethical consideration,
inclusion/exclusion criteria and content of the questionnaire. Data
collection was conducted at baseline and follow-up measurements
at 3 and 12 months after diagnosis and treatment initiation.
Research assessors were blinded to participants’ assignment to
study arms; participants could not be blinded. Baseline assessments
were initiated at the clinic and finalised in the participants’ home
within 3 days from initial contact. Written and oral information
was provided to each of the study participants about the objectives
and process of the study. Written informed consent was a
requirement for enrolment into the trials. An adverse events report-
ing procedure was in place, including a brief protocol to assess sui-
cidality. Serious adverse events were defined as death, suicide
attempt and admission to hospital from any cause. Our strategy
to limit loss to follow-up included: conducting up to three home
visits, contacting by phone in case home visits were unsuccessful,
visiting neighbouring districts in case respondents had migrated
nearby and using a 4 and 8 week period for the assessments for
the short term (midline) and long term (endline), respectively
(2–4 weeks before and 2–4 weeks after the set date for assessments).
A Data Safety Management Committee established by the
Transcultural Psychosocial Organization Nepal with volunteer
members external to the organisation (who had no involvement
in the study funding, design or implementation) reviewed any
reported adverse events. Ethical approval for the RCT was obtained
from the Nepal Health Research Council (NHRC). The cohort
studies were approved by the NHRC, and the ethics boards of the
Faculty of Health Sciences, University of Cape Town, South
Africa and WHO, Geneva, Switzerland. This study is registered
with the International Standard Randomised Controlled Trials
Number (ISRCTN) registry (ISRCTN72875710) (protocol available
at: https://www.isrctn.com/).
Statistical analyses
Based on an estimated 80% power for the primary outcomes and a
10% loss to follow-up, two-sided alpha of 0.05, we aimed to recruit
426 participants in both trials combined. However, the trials were
embedded within a cohort study, so the sample size for the RCT
reflects the number of people diagnosed and recruited in the
cohort studies, therefore placing pragmatic constraints on recruit-
ment for the randomised sample.
We first used non-parametric tests to compare baseline demo-
graphic and health-related characteristics between control and
intervention participants, and between participants retained in the
study and those lost to follow-up within each study arm; we used
the Mann–Whitney U test for continuous variables and Fisher’s
exact test for categorical variables.
The midline and endline effects of HAP and CAP (for depres-
sion and AUD trials, respectively) were assessed by comparing
the mean change in primary outcome scores from baseline
between control and intervention participants in each trial.
The differences in means and 95% confidence intervals for the
PHQ-9 and AUDIT (for depression and AUD trials, respectively)
and for the WHODAS (both trials) were estimated by using
unadjusted negative binomial regression, as none of the scores
were normally distributed. For each trial, imbalances in baseline
characteristics (Mann–Whitney or Fisher’s P< 0.07) were
accounted for by using inverse probability weights: variables on
which treatment and control arm participants differed were
entered as covariates into a logistic regression model to calculate
the probability of being in the treatment arm. The inverse of
that probability was then used as a weight and included in the
negative binomial regressions.31,32
Cohen’s d effect sizes were calculated on all primary outcomes
as the mean difference in change in score from baseline to 3
months, or from baseline to 12 months, between control and inter-
vention arms, divided by the pooled standard error.33,34
Secondary outcomes, the relative risk of reduction to low-risk
drinking levels (for AUD trial, AUDIT < 9) and response (≥50%
reduction of PHQ-9 score for the depression trial) at 3 and 12
months were then assessed. The risk ratios and 95% confidence
intervals were estimated using log-binomial regression, again with
inverse probability weights to account for baseline imbalances
between the two arms.
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Finally, to assess the effect of psychological treatment on func-
tioning (WHODAS) at 3 and 12 months post-recruitment among
people affected by either of the two mental disorders, negative bino-
mial regressions were conducted, this time combining samples from
both trials. Again, any differences in baseline characteristics between
control and treatment arms were accounted for by using inverse
probability weights.
All outcome analyses were on an intention-to-treat basis with
use of multiple imputation for those with missing outcome data.
Continuous variables were imputed using Poisson models, whereas
binary variables were imputed using logistic regression. Sensitivity
analyses were conducted by running the same analyses among all
participants with available data, without imputation.
Results
Sample characteristics
A total of 2044 individuals were approached for the cohort study,16
312 met eligibility criteria of whom 9.6% did not consent to partici-
pate in the study. Of those who provided consent for the cohort
study, 120 (5.9%) received a diagnosis of depression and were
enrolled in the depression trial and 162 (7.9%) received a diagnosis
of AUD and were enrolled in the AUD trial (see Fig. 1). Recruitment
and baseline interviews took place between August 2014 and August
2015, and follow-up interviews occurred between December 2014
and August 2016. Reasons for loss to follow-up included migration
(n = 34), unable to consent to participate (n = 9), unwilling to
participate (n = 11), unavailable for interviews (n = 5) and death
(n = 2).
Table 1 provides an overview of the demographic and clinical
characteristics of participants recruited in each of the two
samples, by arm. Despite the randomisation process, some differ-
ences in baseline demographic characteristics were found. Control
and intervention arms differed (P< 0.07) in terms of education in
the HAP trial and in terms of religion and social support in the
CAP trial.
A total of 8 (13.3%) participants in the depression intervention
arm and 15 participants (18.8%) in the AUD intervention arm
did not receive any counselling sessions. In both depression and
AUD intervention arms, the majority of participants received
between three and five sessions (60.0 and 53.8%, respectively).
For the depression trial participants, the mean number of sessions
was 3.8 (s.d. = 1.99) and the median was 4 (interquartile range 3–
5). For the AUD trial the mean was 3.1 (s.d. = 1.85) and the
median was 3 (interquartile range 2–4) (although CAP is designed
to be a four session intervention, in practice the content was at
times spread out over more sessions as a result of shortened ses-
sions due to limited availability of time among patients). See also
Fig. 2.
In the AUD trial, 16 (19.5%) participants in the control arm and
14 (17.5%) in the intervention arm were lost to follow-up during the
course of the study and did not complete the study. In the depres-
sion trial, this was the case for 9 (15.0%) and 14 (23.3%) participants
in the control and intervention arm, respectively. In the majority of
cases, in both trials (depression: n = 13, 56.5%; AUD: n = 16, 53.3%),
this was due to participants migrating. There were no differences in
baseline demographic or clinical characteristics between these two
groups in the depression trial, although participants lost to
follow-up had marginally greater AUDIT scores at baseline. In
the AUD trial, participants retained in and lost to follow-up from
the study differed in terms of religion and education. (See
Supplementary Table 1 available at https://doi.org/10.1192/bjp.
2018.300).
Depression trial outcomes
The primary and secondary outcomes for the depression trial are
presented in Table 2. At endline (12 month follow-up), the two
arms differed significantly in change in PHQ-9 and WHODAS
scores. At 12 months follow-up in the depression trial, participants
in the HAP arm had a PHQ-9 score reduction of 9.6 (adjusted mean
difference) compared with 5.9 in the control arm (β =−3.7, 95% CI
−5.7 to −1.7, P< 0.001). In the intervention (HAP) arm, the
WHODAS score reduction was 22.9 (adjusted mean difference)
compared with 12.2 in the control arm (β =−10.7, 95% CI −20.0
to −1.5, P= 0.022). Effect sizes for these changes at 12 months
follow-up for symptom reduction were 0.66 (Cohen’s d) and 0.42
for functioning impairment. See Table 2.
At 3 month follow-up in the depression trial, participants in
the intervention (HAP) arm had an adjusted mean change in
PHQ-9 score of −8.7 (95% CI −9.95 to −7.4), compared with
−5.9 (95% CI −7.5 to −4.4) in the control group (95% CI −4.8 to
−0.7, P = 0.009). There was no significant difference in change in
WHODAS scores between the two arms at the 3-month follow-
up, however.
We see a significant between-group difference for response
on the PHQ-9 at 12 months (risk ratio 1.42, 95% CI 1.09–1.85,
P = 0.010). This difference was less pronounced at the 3 month
follow-up (risk ratio 1.28, 95% CI 0.97–1.69, P= 0.076).
Outcomes AUD trial
The primary and secondary results for the AUD trial are presented
in Table 3. Results indicate that the reduction in AUDIT scores from
baseline to the 12 month follow-up between the control (β =−9.78,
95% CI −12.49 to −7.08) and intervention participants (β =−11.948,
95% CI −14.80 to −9.08) did not differ significantly (β =−2.16, 95%
CI −6.10 to 1.79, P= 0.285). Change in WHODAS scores from base-
line to the 12-month follow-up also did not differ between the two
arms (β =−3.55, 95% CI −11.16 to 4.06, P= 0.360). Similarly we
found no significant difference in the rate of reduction to low-risk
drinking levels reported on the AUDIT (risk ratio 1.47, 95% CI
0.87–2.48, P= 0.150). Sensitivity analyses conducted with available
data show similar results for both the depression and AUD trials
(see Supplementary Tables 2 and 3).
Effects of interventions on WHODAS among
participants with AUD or depression
Results of the negative binomial regressions among combined AUD
and depression trial participants demonstrate a small but significant
effect size for change in WHODAS scores from baseline to
endline in favour of the intervention arm (β =−6.04, 95% CI
−11.88 to −0.20, P= 0.042, d = 0.24), although changes from base-
line to midline did not differ between control and intervention
arms (β =−3.53, 95% CI −9.40 to 2.35, P= 0.240, d = 0.14).
Discussion
Psychological treatment (HAP) for depression delivered by commu-
nity-based counsellors confers additional short- and long-term
benefit compared with health worker-delivered, mhGAP-based
standard of care (psychoeducation, pharmacological treatment)
with outcomes of reduced depression symptoms and improved
daily functioning. This means that for treatment of depression in
a primary healthcare setting, there is evidence that adding a brief
psychological treatment has added value, with moderate effect
size, for short- and long-term outcomes.
This result is especially salient given: (a) the relatively small
sample; (b) a comparator condition following evidence-based
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treatment guidelines, representing the current standard of improved
mental healthcare following mhGAP; (c) pragmatic trial conditions
including variance in attendance among participants in the treat-
ment arm – therefore closely representing real-world implementa-
tion; and (d) the long-term effect at 12 month post-treatment
given relapse rates for depression. The effect of the intervention
on functioning is not seen at 3 months but only at 12 months,
which may reflect the longer period needed for symptom reduction
to contribute to improvement in daily functioning.
For AUD, we could not confirm the added value of a counsellor-
delivered psychological treatment over health worker-delivered
mental healthcare alone (consisting of psychoeducation and
pharmacological treatment when indicated) in reducing symptoms
or improving functioning among individuals with AUD. We do see
better results in the CAP arm, however, none of these reached stat-
istical significance. This is contrary to the findings from the CAP
trial in India.22,23 Given the lack of differences between the two
arms, any correlates of change in AUDIT scores at 12 months
would not have been attributable to the CAP intervention. The
possible reasons for the absence of evidence for the added value of
CAP are three-fold: First, it might be explained by the fact that
the CAP is not designed for people with alcohol dependence and
the original trial findings were restricted to participants with
harmful drinking,22 whereas in the current study people with
harmful alcohol use and alcohol dependence are combined to
reflect actual practice.
Allocated to the control
(standard of care) arm
(n= 60)
•  Received allocated
    standard of care (n= 60)
Allocated to intervention
(HAP) arm (n= 60)
•  Received allocated
    additional HAP
    intervention (n= 52)
•  Did not receive additional
    allocated HAP
    intervention (n= 8)
Lost to follow-up (n = 16)
•  Moved away (n= 9)
•  Refused (n = 3)
•  Kept cancelling (n = 1)
•  Death (n = 1)
•  Other (n = 2)
Eligible for RCT (n = 312)
 •  Received diagnosis of depression (n = 137)
 •  Received diagnosis of AUD (n = 175)
Excluded (n = 1732)
 •  Received no diagnosis (n = 1689)
 •  Received diagnosis other than
     depression or AUD (n = 43)
Assessed for eligibility (n = 2044)
Randomised in the depression RCT (n= 120) Randomised in the AUD RCT (n = 162)
Lost to follow-up (n= 9)
•  Moved away (n= 7)
•  Refused (n= 2)
Lost to follow-up (n = 14)
•  Moved away (n= 6)
•  Refused (n= 6)
•  Kept cancelling (n = 1)
•  Hospitalised (n = 1)
Allocated to the control
(standard of care) arm
(n= 82)
•  Received allocated
    standard of care
    intervention (n = 82)
Allocated to intervention
(HAP) arm (n = 80)
•  Received allocated
    additional HAP
    intervention (n = 65)
•  Did not receive
    additional allocated CAP
    intervention (n = 15)
Lost to follow-up (n = 14)
•  Moved away (n= 7)
•  Refused (n = 2)
•  Not found (n = 3)
•  Death (n = 1)
•  Other (n = 2)
Did not consent (n = 30)
Analysed (n = 80)
•  Midline (n= 63)
•  Endline (n = 66)
Excluded from the analysis
(n= 0)
Analysed (n = 82)
•  Midline (n= 67)
•  Endline (n = 66)
Excluded from the
analysis (n = 0)
Analysed (n= 60)
•  Midline (n= 46)
•  Endline (n= 46)
Excluded from the analysis
(n= 0)
Analysed (n= 60)
•  Midline (n= 52)
•  Endline (n= 51)
Excluded from the 
analysis (n= 0)
Fig. 1 Flow diagram of recruitment and follow-up process. AUD, alcohol use disorder; CAP, Counselling for Alcohol Problems; HAP, Healthy
Activity Program; RCT, randomised controlled trial.
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Table 1 Baseline characteristics of the participants recruited in each sample
Depression RCT (N = 120) AUD RCT (N = 162)
N
Standard of care
(N = 60)
Standard of care +
HAP (N = 60)
N
Standard of care
(N = 82)
Standard of care + CAP
(N = 80)
N or med. % or IQR N or med. % or IQR N or med. % or IQR N or med. % or IQR
Gender
Male 18 7 11.7 11 18.3 136 70 85.4 66 82.5
Female 102 53 88.3 49 81.7 26 12 14.6 14 17.5
Age
16–30 27 9 15.0 18 30.0 21 11 13.4 10 12.5
30–50 61 31 51.7 30 50.0 98 45 54.9 53 66.3
>50 32 20 33.3 12 20.0 43 26 31.7 17 21.2
Marital status
No partner 22 7 11.7 15 25.0 10 8 9.8 2 2.5
Has a partner 98 53 88.3 45 75.0 152 74 90.2 78 97.5
Religion
Hindu 102 51 85.0 51 85.0 123* 57* 69.5* 66* 82.5*
Other 18 9 15.0 9 15.0 39* 25* 30.5* 14* 17.5*
Caste
Brahman/Chhetri 48 21 35.0 27 45.0 56 28 34.2 28 35.0
Janajati 35 21 35.0 14 23.3 41 26 31.7 15 18.8
Dalit 29 15 25.0 14 23.3 47 20 24.4 27 33.7
Other 8 3 5.0 5 8.3 18 8 9.8 10 12.5
Educational level
Uneducated/illiterate 36* 22* 36.7* 14* 23.3* 37 18 22.0 19 23.8
Non-formal/less than primary school 35* 21* 35.0* 14* 22.3* 30 17 20.7 13 16.2
Primary school and above 49* 17* 28.3* 32* 53.3* 95 47 57.3 48 60.0
Employment
Not employed 85 43 71.7 42 73.7 36 20 24.4 16 20.2
Employed 32 17 28.3 15 26.3 125 62 75.6 63 79.8
Household food insecurity
No 7 3 5.0 4 7.0 5 3 3.7 2 2.5
Yes 110 57 95.0 53 93.0 156 79 96.3 77 97.5
PHQ-9 score 120 12 5 13 4.5 162 9 7 7.5 6
AUDIT score 120 0 1.5 0 0.5 162 26 9 27 9
WHODAS score 120 38.9 33.3 34.7 22.2 162 18.1 19.4 19.4 26.4
OSS-3 score 117 11 4 10 3 161* 10.5* 3* 12* 3*
RCT, randomised controlled trial; AUD, alcohol use disorder; HAP, Healthy Activity Program; CAP, Counselling for Alcohol Problems; Med., median; IQR, interquartile range; PHQ-9,
Patient Health Questionnaire – 9 item; AUDIT, Alcohol Use Disorder Identification Test; WHODAS, World Health Organization Disability Assessment Schedule; OSS-3, Objective Scoring
System Version 3.
* P < 0.07.
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Fig. 2 Number of sessions per treatment arm. CAP, Counselling for Alcohol Problems; HAP, Healthy Activity Program.
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Table 2 Primary and secondary outcomes at 3 month and 12 month follow-up among intent-to-treat population in the depression sample
Standard of care Standard of care + HAP
Adjusted β or risk ratio
(95% CI) P Cohen’s dN
Adjusted mean score or %
(95% CI)
Adjusted mean change
(95% CI) from baseline N
Adjusted mean score or %
(95% CI)
Adjusted mean change
(95% CI) from baseline
Midline (3 months)a
Primary outcomes
PHQ-9 60 6.15 (4.91–7.39) −5.94 (−7.54 to −4.35) 60 4.36 (3.42–5.30) −8.67 (−9.95 to −7.38) −2.72 (−4.78 to −0.67) 0.009* 0.47
WHODAS 60 23.96 (19.17–28.74) −13.90 (−20.90 to −6.90) 60 15.29 (11.68–18.91) −21.19 (−26.61 to −15.77) −7.29 (−16.14–1.57) 0.107 0.29
Secondary outcomes
Response on PHQ-9b 60 59.0 (52.19–65.41) – 60 77.3 (72.42–81.54) – 1.28 (0.97–1.69) 0.076
Endline (12 months)a
Primary outcomes
PHQ-9 60 6.19 (4.88–7.50) −5.90 (−7.55 to −4.25) 60 3.44 (2.69–4.19) −9.58 (−10.73 to −8.43) −3.68 (−5.68 to −1.67) <0.001** 0.66
WHODAS 60 25.65 (20.34–30.96) −12.21 (−19.58 to −4.84) 60 13.53 (9.75–17.31) −22.95 (−28.49 to −17.42) −10.74 (−19.96 to −1.53) 0.022* 0.42
Secondary outcomes
Response on PHQ-9b 60 56.3 (49.78–62.56) – 60 81.3 (76.66–85.17) – 1.42 (1.09–1.85) 0.010*
HAP, Healthy Activity Program; PHQ-9, Patient Health Questionnaire – 9 item; WHODAS, World Health Organization Disability Assessment Schedule.
a. ‘Standard of care’ group is the reference group.
b. Defined as at least 50% reduction in score compared with baseline.
* P < 0.05, **P < 0.001.
Table 3 Primary and secondary outcomes at 3 month and 12 month follow-up among intent-to-treat population in the alcohol use disorder sample
Standard of care Standard of care + CAP
Adjusted β or risk ratio
(95% CI) P Cohen’s dN
Adjusted mean score or %
(95% CI)
Adjusted mean change
(95% CI) from baseline N
Adjusted mean score or %
(95% CI)
Adjusted mean change
(95% CI) from baseline
Midline (3 months)a
Primary outcomes
AUDIT 82 12.34 (9.93–14.74) −13.15 (−15.97 to −10.33) 80 11.27 (9.08–13.46) −14.97 (−17.59 to −12.35) −1.82 (−5.67 to 2.03) 0.355 0.15
WHODAS 82 14.01 (10.29–17.74) −9.50 (−14.98 to −4.02) 80 12.28 (9.38–15.18) −11.59 (−17.17 to −6.01) −2.09 (−9.90–5.73) 0.601 0.08
Secondary outcomes
Reduction to low-risk drinking levelsb 81 46.1 (37.92–47.58) – 80 57.3 (52.42–62.08) – 1.24 (0.88–1.75) 0.220
Endline (12 months)a
Primary outcomes
AUDIT 82 15.70 (13.43–17.98) −9.78 (−12.49 to −7.08) 80 14.30 (11.83–16.77) −11.94 (−14.80 to −9.08) −2.16 (−6.10–1.79) 0.285 0.17
WHODAS 82 15.51 (12.32–18.70) −8.00 (−13.14 to −2.87) 80 12.31 (9.35–15.27) −11.56 (−17.17 to −5.95) −3.55 (−11.16–4.06) 0.360 0.14
Secondary outcomes
Reduction to low-risk drinking levelsb 81 30.1 (25.56–34.97) – 80 34.4 (29.56–39.57) – 1.47 (0.87–2.48) 0.150
CAP, Counselling for Alcohol Problems; AUDIT, Alcohol Use Disorder Identification Test; WHODAS, World Health Organization Disability Assessment Schedule.
a. ‘Standard of care’ group is the reference group.
b. Defined as subthreshold AUDIT score (<9) at follow-up.
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Second, the newly introduced mhGAP-based standard of care
provided by the health workers is possibly sufficient, which is in
line with evidence for the effectiveness of brief alcohol interventions
within primary care.35 Another study in Nepal showed that the
benefits for people with psychosis and epilepsy were no greater
among those who received psychosocial services in addition to
primary care services.36 It may be that for certain conditions,
simply introducing primary care services carries most of the
variance in improved outcomes.
Third, there could be a methodological explanation in that we
may not have reached the sample for which the study was powered
to detect statistically significant differences. The reason for this is
because the trials were embedded within the larger cohort study,
for which a time restriction for enrolment was applied following con-
sortium guidance. Finally, although it is almost exclusively men
receiving treatment for AUD, the majority of the counsellors were
female. Gender matching in delivering CAP may be better suited
for treatment engagement in Nepali society.
In addition, this study aimed to evaluate an integrated approach
of delivering mental healthcare for multiple disorders by non-spe-
cialist providers. With regards to the outcome of functioning,
perhaps the most salient patient-centred outcome, we see a signifi-
cant improvement for those receiving treatment for depression or
AUD at 12 months.
The study had several limitations. First, despite randomisation we
did find baseline differences between randomised arms. These differ-
ences were statistically controlled for in the analyses. Second, the
study had a small sample and relatively high attrition rate, yet the
attrition rate was not disproportional across the two arms in each
sample. Even with a fixed analysis plan, the fact that the studies
were underpowered increases the risk for a spurious relationship
between treatment and outcome. Future replication studies and
meta-analyses are needed to establish whether found effects were
inflated or deflated.37 Third, the government did not employ the
community-based counsellors as they are not part of the exiting
health system, which in a classic pragmatic trial should be the case.
Fourth, as mentioned above we failed to reach the target sample size.
A strength of this study is that it combined the evaluation of
psychological treatments for both depression and AUD at the
same time, reflecting a more real-world integrated care setting.
The combination of these disorders represents a large proportion
of the global burden caused by mental disorders. Another strength
of the study is that it was embedded in a routine, and less strictly
controlled, care setting that more closely represent low-resource
healthcare settings in most LMICs. This facilitates generalisation
of the findings.
The community-based counsellor-delivered HAP is an effective
intervention for depression, above and beyond health worker deliv-
ered mhGAP-based care (consisting of brief emotional support,
psychoeducation and provision of psychotropic medicines when
indicated), which is sustained and increased at 12 months – demon-
strating long term benefits. For AUD treatment, while a trend for
better results among those that participated in the counsellor-
delivered CAP intervention, this study could not confirm the
added value. For governments and organizations working on the
integration of treatment for depression into primary health care,
this study provides support for the inclusion of psychological
treatments as part of the roll out of mhGAP guidelines provided
by dedicated community-based counsellors.
The study has several implications. First, it shows that commu-
nity-based counsellors delivering psychological treatment adds to
the effectiveness of depression care within a routine primary health-
care in a low-resource setting. In response to the recent Lancet
Commission’s question as to how best to deploy psychological treat-
ment in LMICs, this study provides evidence for a delivery model of
brief and efficacious psychological treatment by community
counsellors in a LMIC setting.7 Second, when following mhGAP
guidelines for the integration of mental health into primary health-
care, it is therefore important to plan and allocate resources for
dedicated psychological workers, such as counsellors, within the
government health system. It is important to note that although
the community-based counsellors in this study are a relatively
low-cost cadre of workers, they received substantial base training
and ongoing supervision, which might be an important ingredient
in explaining the positive results. Third, future implementation
and evaluation of CAP should possibly be restricted to people
with harmful alcohol use and not include alcohol dependence.
This involves further differentiation of the MHCP to ensure that
health workers can distinguish between different degrees of severity
of AUD and that additional treatment for people with alcohol
dependence is also available.
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